Search results
Results from the WOW.Com Content Network
Lutetium (177 Lu) oxodotreotide or 177 Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. [5] It is a radiolabeled somatostatin analog. [3] [6] [7]
DOTA-TATE can be reacted with the radionuclides gallium-68 (T 1/2 = 68 min), lutetium-177 (T 1/2 = 6.65 d) and copper-64 (T 1/2 = 12.7 h) to form radiopharmaceuticals for positron emission tomography (PET) imaging or radionuclide therapy. 177 Lu DOTA-TATE therapy is a form of peptide receptor radionuclide therapy (PRRT) which targets ...
Radiation from lutetium (177 Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney. [45] Arginine/lysine can be used to reduce renal radiation exposure during peptide receptor radionuclide therapy with lutetium (177 Lu) oxodotreotide. [45]
Lutetium (177Lu) oxodotreotide; Lutetium (177Lu) vipivotide tetraxetan; Lutetium phthalocyanine; M. Motexafin lutetium This page was last edited on 4 January 2022 ...
Lutetium compounds are compounds formed by the lanthanide metal lutetium (Lu). In these compounds, lutetium generally exhibits the +3 oxidation state, such as LuCl 3, Lu 2 O 3 and Lu 2 (SO 4) 3. [1] Aqueous solutions of most lutetium salts are colorless and form white crystalline solids upon drying, with the common exception of the iodide.
Naturally occurring lutetium (71 Lu) is composed of one stable isotope 175 Lu (97.41% natural abundance) and one long-lived radioisotope, 176 Lu with a half-life of 37 billion years (2.59% natural abundance).
Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [5] [6] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [6] [8]
Lutetium (177 Lu) chloride is a radioactive compound used for the radiolabeling of pharmaceutical molecules, aimed either as an anti-cancer therapy or for scintigraphy (medical imaging). [ 5 ] [ 6 ] It is an isotopomer of lutetium(III) chloride containing the radioactive isotope 177 Lu , which undergoes beta decay with a half-life of 6.64 days.